Philadelphia, Pennsylvania 19104

  • HIV Seronegativity


The purpose of this study is to see if it is safe to give GENEVAX-HIV, a new HIV vaccine, to HIV-negative volunteers. This study will also look at how this vaccine affects the immune system of these volunteers.

Study summary:

In this open-label study, volunteers are given an intramuscular injection of GENEVAX-HIV vaccine using the Biojector 2000. Safety measures and immune response are assessed accordingly.


Inclusion Criteria You may be eligible for this study if you: - Are 18 - 60 years old. - Are HIV-negative and in good health. - Are able to understand how infections such as HIV are spread. - Agree to use effective methods of birth control during the study. Exclusion Criteria You will not be eligible for this study if you: - Have hepatitis B or C. - Have any condition that may prevent you from completing the study. - Are allergic to bupivacaine, vaccines, or certain local anesthetics. - Have taken certain medications or have received certain therapies that may affect your immune system. - Have an immune system disorder or have received therapy for an immune system disorder. - Have been exposed to HIV within 6 months prior to study entry. - Have received an experimental HIV vaccine or any other experimental treatment within 30 days prior to study entry. - Have received blood transfusions within 6 months prior to study entry. - Abuse alcohol or drugs or have an uncontrolled psychiatric disorder. - Are pregnant or breast-feeding.



Primary Contact:

Study Chair
RR MacGregor

Backup Contact:


Location Contact:

Philadelphia, Pennsylvania 19104
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: June 22, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.